NHS England has put out plans for England to become the first country to eliminate hepatitis C, at least five years prior to the WHO’s target date of 2030. It is hoped that the next round of procurement, which launches in February and deemed to be the largest medicines procurement ever done by the NHS,
A new study conducted by researchers from the University of Southern California in Los Angeles, explains how aerobic and resistance exercise can increase life expectancy for patients who have successfully completed breast cancer treatment. According to National Cancer Institute estimates, in 2017 there were approximately 252,710 new diagnoses of breast cancer in the United States.
A study conducted by the Queen Mary University of London has found that the rise in accident and emergency attendances is being driven by long-term health conditions as opposed to the lack of GP provision. The team of researchers analysed data from nearly 820,000 GP registered patients across 136 practices in East London, and found
As part of the formal launch of our US office in Cambridge, MA, CPL Physicians, a sister brand to UK based Only Medics and part of the Clinical Professionals Group, hosted an event that brought together a number of eminent senior physicians from the greater Boston Biopharma and Med Tech industry. In an intimate dining
NHS England has advised hospitals to defer non-urgent, elective operations and procedures until next month to allow the health service to deal with high pressures over the winter period. According to the National Emergency Pressures Panel (NEPP), the NHS has been under sustained pressure over the Christmas period with high levels of respiratory illness, high
Only Medics, part of the Clinical Professionals group, held their annual Christmas Day, including a bake sale, secret Santa and wearing Christmas jumpers all to aid our corporate charity, Bloodwise.
Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib
It is starting to look highly unlikely that patients with giant cell arteritis will gain NHS access to Roche’s Roactemra, due to the drug being turned down by cost regulators in draft guidelines. NICE’s appraisal committee has emphasised “substantial uncertainties” in the evidence on how long patients would have to take the treatment and what
Ireland-based Alkermes has licensed ALKS 8700 to US biotech Biogen. The drug is a novel, oral, small drug molecule that is currently in Phase III development for relapsing forms of multiple sclerosis. Under the terms of the deal, Biogen will receive exclusive, worldwide license to commercialise the experimental therapy, and will pay Alkermes a mid-teens
Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C. Eli Lilly’s Lartruvo was approved for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues within